Recent research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are revealing promising effects in treating obesity and type non-insulin-dependent diabetes. Preclinical data suggest a unique mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/